Evidence map›Paper›PMID 40894458›Full record

ArticleAmerican heart journal plus : cardiology research and practice2025

Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors.

Javad Jalili, Sarah Vaseghi, Touraj Asvadi, Mahdiyeh Baastani Khajeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Javad JaliliDepartment of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran.
Sarah VaseghiDepartment of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran.
Touraj AsvadiDepartment of Surgery, Tabriz University of Medical Sciences, Tabriz, Iran.
Mahdiyeh Baastani KhajehDepartment of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hemodialysis catheter dysfunction can arise from fibrin sheath formation, leading to impaired patency and compromised treatment. Tissue plasminogen activator (tPA) is an emerging treatment option to restore catheter patency. This study evaluated the efficacy of tPA therapy and explored clinical and demographic risk factors for catheter dysfunction. Methods: This retrospective study included 42 hemodialysis patients with central venous catheters (CVCs) at Results: tPA was effective in 78.6 % of patients after the first dose, restoring both lumens' functionality. Four of the treated cases required a second tPA session due to recurrent fibrin sheath formation within 6-18 months, all of which were successful. Two patients received a third tPA dose 14-16 months after the second, also with complete resolution. Older age ( Conclusion: tPA therapy effectively restores catheter function in cases of fibrin sheath-related dysfunction. Addressing modifiable risk factors such as smoking and managing diabetes may help reduce the incidence of catheter dysfunction and improve long-term outcomes in dialysis patients.

Indexed as

Dialysis catheter dysfunctionFibrin sheathThrombolytic therapyTissue plasminogen activator (tPA)

Identifiers

PMID40894458
PMCPMC12391680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.